N-acetylglucosamine-1-phosphate transferase (GlcNAc-1-phosphotransferase)

N-acetylglucosamine-1-phosphate transferase (commonly abbreviated as GlcNAc-1-phosphotransferase) is an essential eukaryotic enzyme complex that catalyzes the first step in the formation of mannose 6-phosphate (M6P) tags on lysosomal hydrolase precursors[2][1][3][4]. This posttranslational modification occurs in the Golgi apparatus and dictates the sorting and trafficking of hydrolases to the lysosome, a critical pathway for lysosomal function[2][4]. The enzyme complex is a heterohexamer composed of two α, two β, and two γ subunits; the α and β subunits are encoded by the GNPTAB gene, while the γ subunit is encoded by GNPTG[2][1][4]. Inheritied defects in GNPTAB or GNPTG genes disrupt this targeting system, causing lysosomal storage disorders such as mucolipidosis II and III[2][3]. The only known physiological interactions are with newly synthesized lysosomal enzymes and the substrates GDP- or UDP-GlcNAc; no drugs target this enzyme. The molecular structure features several conserved domains and multiple regulatory motifs that enable substrate specificity and activation[1][4]. There are no clinically utilized biomarkers or drugs for direct GlcNAc-1-phosphotransferase modulation. Safety concerns relate almost exclusively to congenital loss of activity, which results in severe systemic disease[2].

Other names

GlcNAc phosphotransferaseGlcNAc-1-phosphotransferaseUDP-N-acetylglucosamine:lysosomal-enzyme N-acetylglucosamine-1-phosphotransferaseGNPTGNPTAB/GNPTG complex

Not applicable/No known approved drugs; theoretical mechanisms would be enzyme inhibition or stabilization